文献速递慢性肾脏病水电解质与酸碱

脯氨酰羟化酶抑制剂能否成为慢性肾脏病贫血的替代治疗?

Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

本文综述了脯氨酰羟化酶抑制剂(PHD-I)治疗慢性肾脏病贫血的机制与临床证据。PHD-I口服给药,通过模拟缺氧激活HIF系统,促进内源性EPO生成及铁吸收利用,维持血红蛋白水平。I/II期研究支持其疗效与安全性,但长期安全性及潜在致癌、眼并发症、肺动脉高压等风险尚待III期研究明确。

要点

  • PHD-I口服,通过抑制PHD激活HIF,促进内源性EPO生成和铁利用。
  • 与ESA不同,PHD-I依靠刺激内源性EPO产生来纠正和维持血红蛋白。
  • 短期I/II期研究支持疗效与安全性,长期安全性和额外获益待III期验证。

核心结论

  • PHD-I是治疗慢性肾脏病贫血极具吸引力的在研药物,可能具有优于ESA的安全性及心血管、骨质疏松和代谢方面的额外优势,但长期安全性尚待III期研究明确。

研究设计与样本

  • 综述性文章,基于多项随访时间较短的I期和II期临床研究证据。

主要发现

  • PHD抑制模拟机体缺氧暴露并激活缺氧诱导因子系统,促进内源性促红细胞生成素产生及铁的吸收和动员。
  • PHD-I为口服给药,与ESA不同,通过刺激内源性EPO产生来纠正和维持血红蛋白水平。
  • I期和II期研究支持PHD-I的疗效和安全性,但随访时间相对较短。
  • PHD-I可能具有优于ESA的安全性,并可能对心血管疾病、骨质疏松和代谢有额外优势。
  • 担忧的不良结局包括癌症加重或新发、眼部并发症或肺动脉高压。

临床怎么用

  • PHD-I为口服制剂,通过刺激内源性EPO产生纠正和维持血红蛋白,与ESA的作用方式不同。
  • 在III期研究结果公布前,需关注PHD-I潜在的癌症、眼部并发症和肺动脉高压等长期安全性问题。

局限性

  • 现有疗效和安全性证据主要来自随访时间较短的I期和II期研究。
  • 长期安全性和潜在优势尚需等待正在进行的III期研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prolyl-hydroxylase (PHD) inhibitors (PHD-I) are the most appealing drugs undergoing clinical development for the treatment of anaemia in patients with chronic kidney disease. PHD inhibition mimics the exposure of the body to hypoxia and activates the hypoxia-inducible factor system. Among many other pathways, this activation promotes the production of endogenous erythropoietin (EPO) and the absorption and mobilization of iron. PHD-I are given orally and, differing from erythropoiesis-stimulating agents (ESAs), they correct and maintain haemoglobin levels by stimulating endogenous EPO production. Their efficacy and safety are supported by several Phases I and II studies with relatively short follow-up. This class of drugs has the potential to have a better safety profile than ESAs and there may be additional advantages for cardiovascular disease (CVD), osteoporosis and metabolism. However, possible adverse outcomes are feared. These span from the worsening or occurrence of new cancer, to eye complications or pulmonary hypertension. The data from the ongoing Phase III studies are awaited to better clarify the long-term safety and possible advantages of PHD-I.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Locatelli F, Del Vecchio L. Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease? Nephrol Dial Transplant. 2020. PMID: 30844045. doi:10.1093/ndt/gfz031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。